# Bioequivalence of a Single-dose of 12 mg IVERMECTIN as Orally Disintegrating Mini Tablets Versus a Single-dose of 12 mg Regular IVERMECTIN Tablets in Healthy Adults Under Fasting Conditions

> **NCT05477810** · EARLY_PHASE1 · COMPLETED · sponsor: **University Children's Hospital Basel** · enrollment: 16 (actual)

## Conditions studied

- Bioequivalence

## Interventions

- **DRUG:** Treatment A (investigational drug) followed by Treatment B (reference drug)
- **DRUG:** Treatment B (reference drug) followed by Treatment A (investigational drug)

## Key facts

- **NCT ID:** NCT05477810
- **Lead sponsor:** University Children's Hospital Basel
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-13
- **Primary completion:** 2022-12-15
- **Final completion:** 2022-12-15
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2022-12-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05477810

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05477810, "Bioequivalence of a Single-dose of 12 mg IVERMECTIN as Orally Disintegrating Mini Tablets Versus a Single-dose of 12 mg Regular IVERMECTIN Tablets in Healthy Adults Under Fasting Conditions". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05477810. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*